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Aims To evaluate safety and effectiveness of early generation drug-eluting stents (DES) compared with bare-metal stents
(BMS) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous
coronary intervention (PCI), and to determine whether benefits and risks vary over time.
Methods and
results
We performed a meta-analysis of 15 randomized controlled trials enrolling a total of 7867 patients comparing
first-generation FDA-approved DES with BMS in patients with STEMI. Random effect models were used to assess
differences in outcomes between DES and BMS among different time periods with regard to the pre-specified
primary outcomes stent thrombosis (ST) and target vessel revascularization (TVR). The overall risk of definite ST
was similar for DES and BMS [risk ratio (RR) ¼ 1.08, 95% CI 0.82–1.43]. However, there were time-dependent
effects, with a RR of 0.80 during the first year (95% CI 0.58–1.12) and 2.10 during subsequent years (95% CI
1.20–3.69), with a positive test for interaction between RR of ST and time (P for interaction ¼ 0.009). Results
were similar for definite or probable ST (P for interaction ¼ 0.015). In the overall analysis, TVR was performed
less frequently in patients with DES when compared with BMS (RR 0.51, 95% CI 0.43–0.61), with a greater
benefit in the first year (RR 0.46, 95% CI 0.38–0.55) when compared with subsequent years (RR 0.75, 95% CI
0.59–0.94; P for interaction ¼ 0.007).
Conclusion An early benefit of early generation DES in primary PCI for STEMI with a reduction in TVR and a trend towards less
definite ST is offset in subsequent years by an increased risk of very late ST.
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Introduction
In patients with ST-segment elevation myocardial infarction
(STEMI), primary percutaneous coronary intervention (PCI)
decreases infarct size and rates of re-infarction, and improves
survival compared with fibrinolysis.1 Bare-metal stents (BMS)
reduce the risk of re-occlusion and re-infarction after PCI,2,3
whereas early generation drug-eluting stents (DES) further
decrease the risk of restenosis and target lesion revascularization
without increasing the incidence of death or myocardial infarction
in a broad spectrum of patients, including STEMI.4,5 However,
there is a higher risk of late and very late stent thrombosis (ST)
associated with DES when compared with BMS,6 which is more
pronounced in patients with STEMI than in patients with stable
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coronary artery disease.7,8 In autopsy specimens of lesions treated
with DES, histopathological analysis shows evidence of delayed
healing due to chronic inflammation, persistent fibrin deposition,
and a greater number of uncovered struts in patients with STEMI
when compared with stable coronary artery disease.9 Optical
Coherence Tomography in patients with STEMI also suggests an
increased risk of uncovered and malapposed struts in lesions
treated with DES when compared with BMS.10
Chronic inflammation and uncovered struts may become
particularly important after cessation of dual antiplatelet therapy
(DAPT) 6 to 12 months after stent implantation, which may cause
the risks and benefits of DES vis-a`-vis BMS to vary over time.11 Pre-
viousmeta-analyses investigating clinical outcomes of DES vs. BMS in
STEMI patients were limited to a maximum follow-up of 2 years,4
were restricted to one type of early generation DES,12,13 or did
not examine differences in relative risks of events over time.4,8 We
therefore set out to investigate the long-term safety and effective-
ness of early generationDES approved by theUS Food andDrugAd-
ministration compared with BMS and to determine whether relative
risks and benefits of DES vs. BMS varied over time.
Methods
Search strategy and selection criteria
We searched Medline, Embase, the Cochrane Central Register of
Controlled Trials (CENTRAL) (Supplementary material online,
Appendix S1), and relevant websites (www.cardiosource.com, www.
clinicaltrialresults.org, www.escardio.org, www.tctmd.com www.
theheart.org) (from the inception of each database to April 2011),
checked conference proceedings, relevant reviews, editorials, and
meta-analyses and reference lists of identified reports for randomized
or quasi-randomized trials in any language that compared sirolimus
eluting stents (SES, Cypher or Cypher Select, Cordis, Miami Lakes,
FL, USA), or paclitaxel eluting stents (PES, Taxus or Taxus Express,
Boston Scientific, Natick, MA, USA) with BMS in adults with STEMI.
Two of the authors (T.P. and G.G.S.) performed screening of
titles and abstracts, reviewed full-text articles, and determined their
eligibility in duplicate.
Data collection and quality assessment
We extracted characteristics of trials, patients, and interventions,
including study design, length of follow-up, components of methodo-
logical quality, and source of funding, gender, diabetes status, and
smoking status of included patients, stent type, reference vessel diam-
eter, number of stents implanted, length and diameter of the implanted
stents, and the recommended duration of DAPT according to the
protocol. As components of methodological quality,14,15 we assessed
concealment of allocation, blinding of investigators adjudicating clinical
events, and the inclusion of all randomized individuals in the analysis
according to the intention-to-treat principle. Concealment of alloca-
tion was considered adequate if the investigators responsible for the
selection of patients did not know before allocation which treatment
was next in line (central randomization, sealed, opaque, sequentially
numbered assignment envelopes, etc.). Any procedures based on pre-
dictable generation of allocation sequences, and potentially transparent
attempts to conceal allocation, such as assignment envelopes which
were not opaque or not sealed,16 were considered inadequate. The
analysis was considered to be according to the intention-to-treat prin-
ciple if all randomized patients were analysed in the group they were
originally allocated to, regardless of the treatment actually received.
All data were extracted by one reviewer (K.H.) and subsequently
checked by a second reviewer (B.K. or B.d.C.).
Outcomes
We pre-specified definite ST as the primary safety outcome and target
vessel revascularization (TVR) as the primary effectiveness outcome.
Definite ST was defined as a thrombosis within the stented segment,
confirmed by angiography or pathology in accordance with the criteria
of the Academic Research Consortium.17 Target vessel revasculariza-
tion was defined as repeat percutaneous intervention or bypass
surgery of the target vessel done for restenosis or other complications.
Data on TVR were unavailable in two trials,18,19 and we used data on
target lesion revascularization as a proxy measure, which was available
for one of the trials.18 We pre-specified the following secondary safety
outcomes: cardiac death, defined as any death due to a cardiac cause
(for example, myocardial infarction, low output failure, fatal arrhyth-
mia), procedure-related deaths, deaths related to concomitant treat-
ment, and death of unknown cause; myocardial infarction, including
fatal and non-fatal non-Q wave or Q wave myocardial infarction; a
composite of death or myocardial infarction. Data on the composite
of death or myocardial infarction were unavailable in eight trials,18–25
and we used data on the composite of cardiac death or myocardial in-
farction as a proxy measure, which was available in two trials.18,19 The
numbers of patients experiencing an event and the overall number of
patients at risk were recorded separately for year 1 and subsequent
years. For two trials,26,27 we obtained additional outcome data for
the follow-up period beyond 1 year. Outcomes data were extracted
by one of the authors (L.R.) and checked by another author (K.H.).
Statistical analysis
We calculated risk ratios (RR) as measures of treatment effect and
used a DerSimonian and Laird random effects model to combine esti-
mates across trials.28 Two three-arm trials had allocated patients to
SES, PES, or BMS and we combined data of SES and PES groups to
derive RRs. First, we performed overall analyses using the maximum
follow-up duration available for each trial. Then, we performed
analyses separately for the first year and for subsequent years
accompanied by tests for interaction between RR and time period
from random-effects meta-regression. We determined heterogeneity
across trials using the I2 statistic and constructed funnel plots (see
Web Supplementary material online, Appendix S2 for details of statis-
tical analysis). Then, we performed analyses stratified by the following
characteristics: adequate concealment of allocation, blind adjudication
of events, adequacy of analyses in accordance with the intention-
to-treat principle, trial size, industry-independent funding, protocol-
mandated duration of DAPT, and type of DES. We derived
numbers-needed-to-treat (NNTs) and numbers needed-to-harm
(NNHs) to prevent or cause one additional event per year when com-
pared with BMS from baseline event rates in BMS arms and the pooled
RR comparing DES and BMS.29 Assumptions for baseline event rates
were based on median annual event rates in year 1 and in subsequent
years found in BMS arms of included trials and registry studies7,30–34
comparing first generation DES with BMS in patients with STEMI
with at least 300 patients in the BMS group (Supplementary material
online, Appendix S3). Numbers-needed-to-treat and NNHs were cal-
culated separately for year 1, for years 2–5, and for the entire
period of 1–5 years. All analyses were performed using STATA 11.2.
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Table 1 Clinical characteristics of trials
Trial acronym Stent type No. of
patients
Age,
mean
(SD)
Males,
n (%)
Diabetes,
n (%)
Hypertension,
n (%)
Smokers,
n (%)
MVD,
n (%)
RVD,
mean
(SD)
No. of
stents,
mean
(SD)
Stent
length,
mean
(SD)
Stent
diameter,
mean (SD)
Longest
FUP,
years
Pasceri et al. SES/BMS 32/33 62 (–) – – – – – – – – – 3
PASSION PES/BMS 310/309 61 (13) 470 (76) 68 (11) 193 (31) 319 (52)a 278 (45) 3.2 (0.5) 1.3 (0.6) 19 (6) 3.2 (0.3) 5
STRATEGY SES/BMS 87/88 63 (12)b 128 (73) 26 (15) 92 (53) 70 (40) 72 (41) 2.3 (0.5)b – – – 5
BASKET-AMI SES/PES/BMS 75/67/74 – – – – – – – – – – 3
TYPHOON SES/BMS 356/359 59 (12) 558 (78) 116 (16) 289 (41) 356 (50) 336 (47) 2.8 (0.6) 1.1 (0.4) 21 (8) 3.1 (0.4) 4
PASEO SES/PES/BMS 90/90/90 62 (16) 190 (70) 69 (26) 71 (26) 68 (25) – 3.2 (0.5) 1.2 (0.5) 21 (7) 3.1 (0.4) 6
SESAMI SES/BMS 160/160 63 (12) 256 (80) 65 (20) 185 (58) 174 (54) 150 (47) – 1 (–) 18 (4) 3.1 (0.2) 3
MISSION SES/BMS 158/152 59 (11) 241 (78) 30 (10) 87 (28) 169 (55) 106 (34) 2.8 (0.6) – 26 (12) 3.3 (0.3) 3
HAAMU-STENT PES/BMS 82/82 63 (13) 118 (72) 24 (15) 75 (46) 70 (43) – – – – – 1
Dı`az de la Llera SES/BMS 60/60 65 (13) 95 (79) 33 (28) – 82 (68) 56 (47) – – 30 (15) 3.2 (0.4) 1
MULTI-STRATEGY SES/BMS 373/372 64 (12) 565 (76) 108 (15) 426 (57) 277 (37) 399 (53) 2.8 (0.4)b 1 (0) 22 (5) 3.1 (0.4) 3
SELECTION PES/BMS 40/40 61 (–) 66 (83) 10 (13) 37 (46) 43 (54) 36 (45) 2.9 (0.4) – 20 (5) 3.1 (0.3) 7 mo.
GRACIA-3 PES/BMS 217/216 61 (1) 358 (83) 80 (18) 188 (43) 210 (48) 163 (38) 2.9 (0.04) – – – 1
HORIZONS-AMI PES/BMS 2257/749 60 (–)b 2307 (77) 478 (16) 1544 (51) 1429 (48) – 2.9 (0.5)a 1.5 (0.8) 30 (16) – 3
DEDICATION DES/BMSc 313/313 62 (–) 458 (73) 65 (10) 207 (33) 336 (54) 235 (38) – – 22 (10) 3.5 (0.5) 3
aIncludes all patients with a history of smoking, not just current smokers.
bEstimated mean and SD from median and IQR.
cDEDICATION compares different types of DES without differentiating between SES and PES.
FUP, follow-up; MVD, multivessel disease; RVD, reference vessel diameter; PASSION, paclitaxel-eluting stent vs. conventional stent in myocardial infarction with ST-segment elevation; STRATEGY, Single High Dose Bolus Tirofiban and
Sirolimus Eluting Stent vs. Abciximab and Bare Metal Stent in Myocardial Infarction; BASKET-AMI, Basel Stent Kosten Effektivita¨ts in Acute Myocardial Infarction Trial; TYPHOON, Trial to Assess the Use of the Cypher Stent in Acute
Myocardial Infarction Treated with Balloon Angioplasty; PASEO, Paclitaxel or Sirolimus-Eluting Stent vs. Bare Metal Stent in Primary Angioplasty; SESAMI, Sirolimus-Eluting Stent vs. Bare-Metal Stent in Acute Myocardial Infarction; MISSION, A
Prospective Randomised Controlled Trial to Evaluate the Efficacy of Drug-Eluting Stents vs. Bare-Metal Stent in Acute Myocardial Infarction Study; HAAMU-STENT, Helsinki Area Acute Myocardial infarction treatment reevalUation—should
the patient get a drug-Eluting or a Normal sTent; MULTI-STRATEGY, Multicenter Evaluation of Single High-Dose Bolus Tirofiban vs. Abciximab with Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study;
SELECTION, Single-Center Randomized Evaluation of Paclitaxel-Eluting Versus Conventional Stent in Acute Myocardial Infarction; GRACIA-3, Grupo de Ana`lisis de la Cardiopatı`a Isque´mica Aguda; HORIZONS-AMI, Harmonizing Outcomes
with Revascularization and Stents in Acute Myocardial Infarction; DEDICATION, Drug Elution and Distal Protection in ST-Segment-Elevation Myocardial Infarction.
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Figure 1 Number of patients experiencing definite ST out of the total patients DES and BMS. Risk ratios with 95% CI for definite stent
thrombosis comparing DES vs. BMS for individual trials and the pooled trials. DES, drug-eluting stent; BMS, bare-metal stent; ST, stent
thrombosis.
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Results
We identified 558 references in our literature search and consid-
ered 43 to be potentially eligible (Supplementary material online,
Appendix S2). Forty reports describing 15 trials met our inclusion
criteria and were included in the meta-analysis,18–27,35–59 13 pub-
lished as full-text journal articles, and 2 presented at scientific
meetings only. The trials had randomly allocated 7867 patients
undergoing primary PCI in the setting of STEMI to treatment
with either early generation DES or BMS. Seven trials allocated
patients to SES,20,21,23,24,26,27,35 and five to PES.18,19,22,37,38 Three
trials used both types of DES,25,39,44 two had three arms,39,44
and one had two arms, with the implantation of SES (47%), PES
(40%), or Zotarolimus-eluting stents (13%) in patients in the
DES arm remaining at the discretion of the treating physician.25
The methodological characteristics of trials are summarized in
Supplementary material online, Appendix S5. All trials were described
as randomized. Concealment of allocation was adequate in four
trials.19,24,25,37 Blind adjudication of events was described in eight
trials;18,19,21,26,27,37,39,44 in one trial,23 a clinical events committee
was described to adjudicate events, but it remained unclear whether
members of the committee were aware of the assigned stent type.
Seven trials had analysed their data according to the intention-to-treat
principle.18,20,25,27,37,38,44 The maximum length of follow-up ranged
from 7 months to 6 years with a duration of follow-up of 3 years or
more in 11 trials.18–21,23–27,37,39,44 Three trials reported funding to
be completely independent from industry.18,19,27 The clinical charac-
teristics of included patients are summarized in Table 1. The mean
age ranged from 59 to 65 years, the percentage of males from 70 to
83%, the percentage of patients with diabetes from 10 to 28%, and
the percentage of patients with multi-vessel disease from 34 to 53%.
A loading dose of clopidogrel 300 mg was administered in nine
trials18,19,23,24,26,27,38,39,44 and 300–600 mg in four trials,21,25,35,37
whereas two trials did not report the loading dose.20,56 The duration
of DAPT recommended according to protocol for patients with DES
ranged from3 to12months, with identical recommendeddurations in
DES and BMS patients in all but one trial.35 Glycoprotein IIb/IIIa inhibi-
tors were administered in .95% of the patients in 11 out of 15
trials,19–21,24–27,35,37,38,44 in 71 and 74% of the patients in two trials
use;18,23 two other trials did not report the rate of GpIIb/IIIa inhibitor
use39,56 (Supplementary material online, Appendix S3). The use of
mechanical thrombo-aspirationwas not reported, with the exception
of one trial (4% of patients),44 whereas a filterwire was reported in
another trial (41% of the patients).54 Angiographic follow-up was
performed in six trials, in 24–95% of the patients.19–21,23,37,38
All 15 trials contributed to the analysis of the primary safety end-
point of definite ST, which was reported in 151 patients treated with
DES (3.2%) and 83 patients allocated to BMS (2.7%). Nine trials
reported ST based on ARC definitions.19,23–26,37–39,44 Figure 1
(top) presents the Forest plot with RRs of individual trials scattered
around the null effect line at 1, a pooled RR of 1.08 (95% CI 0.82–
1.43) and no evidence for heterogeneity between trials (I2 ¼ 0%,
Figure 2 Contour enhanced funnel plots for definite ST and TVR with log of the RR of individual trials on the x-axis scattered against the
corresponding standard error on the y-axis. The larger a trial, the more events accumulated, the smaller the standard error as a measure of
statistical precision. In the absence of bias, the scatter of trials should have the shape of an inverted funnel, with large trials scattering little at the
top and small trials scattering considerably at the bottom. If the funnel plot is asymmetrical, this suggests the presence of small study effects,
suggesting that methodological problems, selective reporting of outcomes in small trials, and publication bias may have resulted in an overesti-
mation of effects. Red solid lines are prediction lines from univariable meta-regression models with standard error as explanatory variable and
red broken lines are corresponding 95% prediction intervals. The more the prediction line deviates from the vertical line, the more pronounced
is asymmetry. Contours distinguish between grey areas of significance at a two-sided P ≤ 0.05 and white areas of non-significance at a two-sided
P . 0.05. If trials seem to be missing in areas of non-significance, this adds to the notion of the presence of bias. The prediction lines should be
interpreted independently of contours. P-values are from the Harbord test. ST, stent thrombosis; TVR, target vessel revascularization.
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P for heterogeneity ¼ 0.83). Figure 2 (left) presents the correspond-
ing funnel plot. The scatter of effect estimates and the prediction line
frommeta-regression models with standard error as an explanatory
variable indicated complete symmetry, with all trials in white areas
of non-significance at P. 0.05. The regression test was negative
(P ¼ 0.69). Stratified analyses according to the methodological
and clinical characteristics of trials (Table 2, left) showed only
minor variation across strata and corresponding tests for interaction
were negative. Figure 1 shows forest plots of definite ST occurring
during the first year (middle) and subsequent years (bottom).
During the first year after stent implantation, patients with DES
tended to be less likely than patients with BMS to experience defin-
ite ST (RR 0.80, 95% CI 0.58–1.12). Conversely, patients with DES
were more likely than patients with BMS to experience definite ST
during subsequent years (RR 2.10, 95% CI 1.20–3.69), and a test of
interaction between RR of definite ST and time was positive (P for
interaction ¼ 0.009). Results were similar for the composite of
definite or probable ST; definite or probable ST during the first
year tended to be less likely in patients with DES than with BMS
(RR 0.81, 95% CI 0.60–1.11), whereas the risk during subsequent
years was greater (RR 2.01, 95% CI 0.79–1.31), with a positive
test for interaction (P for interaction ¼ 0.015).
Fourteen trials contributed to the analysis of the primary
efficacy endpoint TVR, which was performed in 429 patients
treated with DES (9.0%) and 452 patients treated with BMS
(14.6%), with a pooled RR of 0.51 (95% CI 0.43–0.61, Figure 3,
top) and no evidence for heterogeneity between trials (I2 ¼ 24%,
P for heterogeneity ¼ 0.19). Figure 2 (right) presents the
corresponding funnel plot. The scatter of effect estimates and
the prediction line from meta-regression models with standard
error as an explanatory variable indicated asymmetry and the
contours to distinguish between areas of significance and non-
significance at P ¼ 0.05 suggested missing trials in the white area
of non-significance. The regression test for asymmetry was positive
at P ¼ 0.002. Accordingly, stratified analyses according to the
methodological and clinical characteristics indicated a greater
benefit from DES in small when compared with large trials
(Table 2, right). In the analysis stratified according to the time
(Figure 3, middle and bottom), we found a more pronounced
reduction in the relative risk of TVR for DES when compared
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Table 2 Stratified analysis by characteristics of trials and stent type for overall follow up
Definite stent thrombosis Target vessel revascularization
No. of
trials
No. of
patients
DES vs. BMS I2 P-inter No. of
trials
No. of
patients
DES vs. BMS I2 P-inter
All trials 15 7867 1.08 (0.82–1.43) 0 14 7431 0.51 (0.43–0.61) 24
Adequate concealment of allocation 0.56 0.18
Yes 4 4388 1.00 (0.69–1.46) 0 3 3952 0.58 (0.43–0.80) 50
No/unclear 11 3479 1.19 (0.78–1.82) 0 11 3479 0.47 (0.38–0.57) 0
Blind adjudication of events 0.71 0.85
Yes 9 6403 1.11 (0.81–1.51) 0 8 5967 0.50 (0.39–0.65) 51
No/unclear 6 1464 0.96 (0.49–1.88) 0 6 1464 0.48 (0.36–0.65) 0
Intention to treat analysis 0.95 0.59
Yes 7 4841 1.07 (0.75–1.53) 0 7 4841 0.51 (0.38–0.67) 50
No/unclear 8 3026 1.09 (0.69–1.73) 0 7 2590 0.48 (0.37–0.62) 0
Trial size 0.99 0.043
.300 8 6777 1.08 (0.80–1.46) 0 7 6341 0.57 (0.47–0.70) 29
,300 7 1090 1.08 (0.47–2.45) 0 7 1090 0.36 (0.26–0.51) 0
Funding independent from industry 0.59 0.58
Yes 3 1230 1.09 (0.33–3.66) 33 2 794 0.56 (0.31–1.02) 46
No/unclear 12 6637 1.05 (0.78–1.41) 0 12 6637 0.50 (0.41–0.60) 28
Type of stent 0.99 0.10
SES 9 1391 1.14 (0.72–1.81) 0 8 1035 0.45 (0.34–0.59) 0
PES 6 2998 1.15 (0.79–1.66) 0 6 2779 0.58 (0.43–0.79) 32
Protocol mandated duration of DAPT 0.40 0.58
9 or 12 months 7 2056 0.83 (0.42–1.61) 0 6 1620 0.47 (0.35–0.61) 0
3 or 6 months 8 5811 1.14 (0.84–1.56) 0 8 5811 0.51 (0.39–0.66) 47
Note that one two-arm trial did not contribute to the analysis according to stent type since different stent types were used in the DES arm, and two three-arm trials allowed both
a comparison of SES with BMS and a comparison of PES with BMS. Therefore, 16 comparisons are reported in stratified analysis according to stent type. P-inter, P for interaction
between subgroups using meta regression.
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Figure 3 Number of patients requiring TVR among all total patients in DES and BMS. Risk ratios for definite stent thrombosis comparing DES
vs. BMS for individual trials and the pooled population. DES, drug-eluting stent; BMS, bare-metal stent; ST, stent thrombosis; TVR, target vessel
revascularization.
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with BMS during the first year (RR 0.46, 95% CI 0.38–0.55) as
opposed to subsequent years (RR 0.75, 95% CI 0.59–0.94), with
a positive test of interaction between RR of TVR and time (P for
interaction ¼ 0.007, Figure 4, top).
Sensitivity analyses of time-dependent effects after restriction to
trials of higher methodological quality showed similar results as the
main analysis for both primary endpoints (Table 3). Stratified ana-
lyses according to the stent type also suggested similar results
for definite ST, but more pronounced time-dependent effects for
TVR with SES than with PES, even though confidence intervals
were wide and overlapping (Table 3). A post hoc analysis of
time-dependent effects after exclusion of the largest trial,
HORIZONS-AMI,37 yielded again similar results. For definite ST,
the RR was 0.75 during the first year (95% CI 0.47–1.18) and
2.06 during subsequent years (95% CI 1.02–4.15; P for
interaction ¼ 0.028). For TVR, the RR was 0.39 during the first
year (95% CI 0.32–0.48) and 0.80 during subsequent years (95%
CI 0.54–1.19; P for interaction ¼ 0.005).
Figure 4 presents full analyses of primary and secondary outcomes
overall and stratified according to the time period. We found vari-
ation across time periods for definite ST, TVR, MI, and the
composite of definite or probable ST, all with positive tests for inter-
action between treatment effect and time (P for interaction
≤0.015). For remaining outcomes, there was no evidence to
suggest time-dependent effects. Table 4 presents estimated NNTs
to prevent one event and NNHs to cause one event during the
first year and subsequent years and for the entire duration of follow-
up for all outcomes. The NNT to prevent one definite ST compared
with BMS during the first year was 238, but the estimate did not
reach conventional levels of statistical significance (P ¼ 0.17) and
the 95% CI included infinity (95% CI 114 to 1). The NNH to
cause one additional definite ST during the subsequent 4 years
was 76 (95% CI 31–417, P ¼ 0.009). Taken together, this resulted
in a NNH to cause one additional definite ST over 5 years of 111,
with the 95% CI, including infinity (95% CI 21 to 1, P ¼ 0.46).
Numbers-needed-to-treat of 19 were reached to avoid one TVR
during the first year (95% CI 16–23), 71 during the subsequent 4
years (95% CI 44–298), and 15 for years 1–5 combined (95% CI
11–27), with all estimates reaching conventional levels of statistical
significance (P ≤ 0.015). Additional statistical trends were only
observed for MI, with a NNT of 79 to prevent one MI during the
first year (95% CI 49–355, P ¼ 0.01) and a NNH of 76 to cause
Figure 4 Risk of clinical outcomes comparing DES with BMS stratified according to time. DES, drug-eluting stent; BMS, bare-metal stent.
P-inter: P for interaction between year 1 and subsequent years using meta-regression.
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one MI compared with BMS during the subsequent 4 years (95% CI
29 to 1, P ¼ 0.10). Taken together, this resulted in a clinically
irrelevant NNH of 1961 to cause one MI during years 1–5 (95%
CI 22 to 1, P ¼ 0.98).
Discussion
This meta-analysis of 15 randomized trials in 7867 patients who
underwent primary PCI for STEMI suggests time-dependent clinical
effects of early generation FDA-approved DES compared with
BMS for definite ST, definite or probable ST, TVR, and myocardial
infarction. During the first year, there was a safety advantage of
DES over BMS in terms of lower rates of ST and MI, whereas an
opposite pattern emerged during subsequent years, with a safety
advantage of BMS over DES. This qualitative interaction between
risks and benefits was particularly robust for the endpoint definite
ST, with a trend towards a 20% relative risk reduction during the
first year, which was offset by a more than 100% relative risk
increase during subsequent years (P for interaction ¼ 0.009). For
the primary effectiveness outcome of TVR, we did not find a quali-
tative, but still an important quantitative interaction, with a more
than 50% relative risk reduction in TVR during the first year,
which decreased but was maintained at 25% during subsequent
years (P for interaction ¼ 0.007). Overall, the effectiveness of
DES in reducing the rate of TVR was maintained across the
entire duration of follow-up, with an estimated NNT to prevent
one TVR during the first 5 years after stent implantation of 15,
which is clearly clinically relevant. For none of the safety outcomes,
we found any evidence for overall risk increases associated with
DES, with risk ratios near one for death overall, cardiac death,
MI, ST, and the composite of death or MI. Conversely, there was
clear evidence of late harm with an increased risk of definite and
definite or probable ST as well as MI.
What does this meta-analysis add in comparison with previously
published systematic reviews? First, we included 15 studies with a
total of 7867 patients. Therefore, this is the largest meta-analysis of
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 3 Sensitivity analysis of time-dependent effects after restriction of trials of higher methodological quality and
after stratification according to stent type
Definite stent thrombosis Target vessel revascularization
No. of
trials
No. of
patients
DES vs. BMS I2 P-inter No. of
trials
No. of
patients
DES vs. BMS I2 P inter
All trials 0.009 0.007
Year 1 15 7867 0.80 (0.58–1.12) 0 14 7431 0.46 (0.38–0.55) 6
Subsequent years 11 7067 2.10 (1.20–3.69) 0 11 7067 0.75 (0.59–0.94) 0
Trials with concealed allocation 0.20 0.26
Year 1 4 4388 0.82 (0.53–1.27) 0 3 7904 0.50 (0.33–0.76) 54
Subsequent years 3 3952 1.61 (0.73–3.57) 0 3 7904 0.73 (0.56–0.95) 0
Trials with blind adjudication 0.019 0.063
Year 1 9 6403 0.82 (0.57–1.18) 0 8 5967 0.44 (0.33–0.59) 40
Subsequent years 8 5967 2.21 (1.18–4.14) 0 8 5967 0.71 (0.56–0.91) 0
Trials with ITT analysis 0.068 0.30
Year 1 7 4841 0.81 (0.53–1.23) 0 7 4841 0.49 (0.37–0.65) 28
Subsequent years 6 4761 1.95 (0.96–3.95) 0 6 4761 0.67 (0.52–0.86) 0
Large trials 0.016 0.022
Year 1 8 6777 0.79 (0.56–1.14) 0 7 6341 0.48 (0.37–0.61) 34
Subsequent years 7 6341 2.12 (1.17–3.84) 0 7 6341 0.79 (0.62–1.01) 0
Trials with industry independent funding 0.21 0.67
Year 1 3 1230 0.69 (0.23–2.07) 0 2 794 0.52 (0.26–1.04) 43
Subsequent years 2 794 3.99 (0.85–18.6) 0 2 794 0.70 (0.30–1.64) 0
SES 0.096 0.027
Year 1 9 2779 0.83 (0.47–1.47) 0 8 2064 0.35 (0.25–0.48) 0
Subsequent years 8 2567 2.18 (0.91–5.23) 0 7 1868 0.80 (0.45–1.42) 0
PES 0.053 0.42
Year 1 6 4485 0.84 (0.55–1.30) 0 6 4408 0.60 (0.47–0.76) 0
Subsequent years 3 3657 2.57 (1.15–5.72) 0 4 4008 0.70 (0.54–0.92) 0
P-inter, P for interaction between year 1 and subsequent years using meta regression.
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its kind. Secondly, we focused on long-term outcomes, and provide
the longest follow-up reported to date with a maximum length of
follow-up up to 6 years. This is important as previous large-scale
trials and meta-analyses failed to detect differences in late safety
outcomes with the use of early generation DES, prematurely con-
cluding the absence of harm among STEMI patients. Thirdly, we
examined the data for the presence of small study effects using
contour-enhanced funnel plots and regression tests. Finally and
most importantly, we systematically analysed time-dependent
effects of stent-type allocation on all clinical outcomes (Figure 4).
Our analysis indicates that the use of early generation DES is asso-
ciated with a significantly lower risk of TVR and MI as well as a
trend towards fewer definite ST during the period of up to 1
year, whereas a reverse pattern of a higher risk of definite ST
and a trend towards more MIs becomes apparent during the
period beyond 1 year. This suggests that the long-term safety of
DES needs further improvement.
Patients with STEMI are at increased risk of ST when compared
with patients with stable coronary artery disease both after DES
and after BMS implantation.7,8,60 However, the observed differen-
tial in timing of ST suggests differences in the underlying patho-
physiological pathways leading to this adverse event after DES
implantation. Thus, early ST is closely related to the acute phase
after the coronary event and procedure, with pronounced activa-
tion of platelets and the coagulation cascade. In this context,
experimental data suggest that durable polymer-based DES exert
anti-thrombogenic properties resulting in a lower degree of throm-
bus adhesion,61 which may be of particular importance among
STEMI patients. Along this line, the results of the present study
provide preliminary clinical evidence of a somewhat lower risk of
definite ST and MI after DES when compared with BMS implant-
ation among STEMI patients. Conversely, ST occurring later in
the process may be related to a chronic process with delayed
arterial healing and vessel remodelling due to chronic local inflam-
mation potentially related to the persistence of durable polymers62
and/or long-term effects of eluted drugs. Along this line, autopsy
data indicate a differential healing response of DES implanted
into plaques of patients with STEMI when compared with stable
coronary artery disease with evidence of persistent inflammation
and a higher proportion of uncovered struts among coronary seg-
ments treated with DES than BMS.9 Among patients treated with
DES, incomplete stent apposition has been recognized as an im-
portant morphological substrate associated with the occurrence
of very late ST.63 It is more frequently observed in STEMI patients
than in those who undergo DES implantation for stable angina and
may be related to incomplete stent apposition at the time of im-
plantation, presence of jailed thrombus with subsequent reso-
lution, or vessel remodelling in response to toxic effects of the
drug or polymer. In addition, optical coherence tomography10
and intravascular ultrasound studies52 among STEMI patients
provide evidence for a higher rate of uncovered stent struts as
well as incomplete stent apposition in DES compared with BMS.
All these factors may be of particular relevance upon discontinu-
ation of DAPT during long-term follow-up.
The higher risk of definite ST with early generation DES than
BMS more than 1 year after stent implantation directly translated
into an increased risk of myocardial infarction, with identical
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NNHs of 76 to cause one event for both ST and MI. Whether pro-
longation of DAPT beyond 1 year among patients with STEMI who
are at a higher risk of very late ST compared with other patient
subsets may overcome this disadvantage, which could in turn trans-
late into a lower overall relative risk of ST and MI, remains subject
to debate. In addition, the use of newer generation DES with
durable polymers of improved biocompatibility,64 biodegradable
polymers which dissolve completely once the drug is eluted,11
or even fully bioresorbable vascular scaffolds65 are currently
being investigated to address this issue in STEMI patients.66,67
This meta-analysis demonstrated a sustained benefit of DES
when compared with BMS in reducing the risk of TVR. The mag-
nitude of the relative risk reduction of approximately 50% was
comparable to what was found in randomized trials of patients
with stable coronary artery disease and is clinically important
with a NNT of only 15.5 The relative risk reduction in TVR
observed during the first year decreased considerably during
subsequent years, however (P for interaction ¼ 0.007).68 The
decrease in benefit over time was previously referred to as late
catch-up phenomenon69 and some studies found DES associated
with delayed late lumen loss beyond the first year of follow-up.68,70
Our results suggest that the increased rate in VLST requiring
repeat intervention might contribute to this phenomenon. We
were also surprised to find evidence of small study effects71,72
for TVR, suggesting that methodological problems14 and selective
reporting of outcomes73 in small trials combined with publication
bias74 may have resulted in an overestimation of the effectiveness
of first-generation DES.
Conclusions
The use of early generation DES in primary PCI for STEMI is asso-
ciated with a large reduction in TVR and a trend towards less def-
inite ST during the first year, which is offset by an increased risk of
very late ST and accompanying clinical outcomes during subse-
quent years.
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